David A Cooper
Overview
Explore the profile of David A Cooper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
320
Citations
9997
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cooper D, DePaolo-Boisvert J, Nicholson S, Gad B, Minh D
J Chem Inf Model
. 2025 Jan;
65(3):1465-1475.
PMID: 39824514
It has been challenging to determine how a ligand that binds to a receptor activates downstream signaling pathways and to predict the strength of signaling. The challenge is compounded by...
2.
Minh D, Cooper D, Xie B, Shi L
J Chem Theory Comput
. 2025 Jan;
21(2):943-950.
PMID: 39804153
We have developed a method that uses energy landscapes of unbound and bound ligands to compute reorganization free energies for end-point binding free-energy calculations. The method is applied to our...
3.
Cooper D, DePaolo-Boisvert J, Nicholson S, Gad B, Minh D
bioRxiv
. 2024 Dec;
PMID: 39677660
It has been challenging to determine how a ligand that binds to a receptor activates downstream signaling pathways and to predict the strength of signaling. The challenge is compounded by...
4.
Fakih H, Tang Q, Summers A, Shin M, Buchwald J, Gagnon R, et al.
Mol Ther Nucleic Acids
. 2023 Dec;
34:102080.
PMID: 38089931
Although an increasing number of small interfering RNA (siRNA) therapies are reaching the market, the challenge of efficient extra-hepatic delivery continues to limit their full therapeutic potential. Drug delivery vehicles...
5.
Tang Q, Fakih H, Zain Ui Abideen M, Hildebrand S, Afshari K, Gross K, et al.
Nat Commun
. 2023 Nov;
14(1):7099.
PMID: 37925520
Inhibition of Janus kinase (JAK) family enzymes is a popular strategy for treating inflammatory and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors show distinct efficacy and safety...
6.
Hariharan V, Shin M, Chang C, OReilly D, Biscans A, Yamada K, et al.
Proc Natl Acad Sci U S A
. 2023 Mar;
120(11):e2219523120.
PMID: 36893269
The continuous evolution of SARS-CoV-2 variants complicates efforts to combat the ongoing pandemic, underscoring the need for a dynamic platform for the rapid development of pan-viral variant therapeutics. Oligonucleotide therapeutics...
7.
Biscans A, Ly S, McHugh N, Cooper D, Khvorova A
J Control Release
. 2022 Aug;
349:831-843.
PMID: 35917865
Lipid conjugation supports delivery of small interfering RNAs (siRNAs) to extrahepatic tissues, expanding the therapeutic potential of siRNAs beyond liver indications. However, siRNA silencing efficacy in extrahepatic tissues remains inferior...
8.
Tang Q, Sousa J, Echeverria D, Fan X, Hsueh Y, Afshari K, et al.
Mol Ther
. 2022 Apr;
30(8):2709-2721.
PMID: 35477658
Aberrant activation of interferon (IFN)-γ signaling plays a key role in several autoimmune skin diseases, including lupus erythematosus, alopecia areata, vitiligo, and lichen planus. Here, we identify fully chemically modified...
9.
Granger L, Huettner I, Debeljak F, Kaleebu P, Schechter M, Tambussi G, et al.
AIDS
. 2021 Jun;
35(13):2073-2084.
PMID: 34127581
Objective: Development of immunogens that elicit an anti-HIV-1 broadly neutralizing antibody (bnAb) response will be a key step in the development of an effective HIV-1 vaccine. Although HIV-1 bnAb epitopes...
10.
Aung W, Myint N, Zaw T, Cooper D, Aung N, Kyi M, et al.
Am J Trop Med Hyg
. 2020 Feb;
102(4):884-888.
PMID: 32100684
The impact of HIV infection on the burden of gastrointestinal pathogens in Myanmar is poorly defined. Stools of 103 HIV-infected and 105 HIV-uninfected adult outpatients at a tertiary referral hospital...